FR3123357B1 - Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine - Google Patents

Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine Download PDF

Info

Publication number
FR3123357B1
FR3123357B1 FR2105529A FR2105529A FR3123357B1 FR 3123357 B1 FR3123357 B1 FR 3123357B1 FR 2105529 A FR2105529 A FR 2105529A FR 2105529 A FR2105529 A FR 2105529A FR 3123357 B1 FR3123357 B1 FR 3123357B1
Authority
FR
France
Prior art keywords
seq
conformers
fiber
syn
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2105529A
Other languages
English (en)
Other versions
FR3123357A1 (fr
Inventor
Alix Bouvier-Müller
Frédéric Duconge
Luc Bousset
Ronald Melki
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Centre National de la Recherche Scientifique CNRS
Commissariat a lEnergie Atomique CEA
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Commissariat a lEnergie Atomique CEA, Commissariat a lEnergie Atomique et aux Energies Alternatives CEA filed Critical Centre National de la Recherche Scientifique CNRS
Priority to FR2105529A priority Critical patent/FR3123357B1/fr
Priority to US18/564,121 priority patent/US20240240191A1/en
Priority to PCT/FR2022/050993 priority patent/WO2022248805A1/fr
Priority to EP22732601.4A priority patent/EP4347838A1/fr
Priority to JP2023572981A priority patent/JP2024520044A/ja
Publication of FR3123357A1 publication Critical patent/FR3123357A1/fr
Application granted granted Critical
Publication of FR3123357B1 publication Critical patent/FR3123357B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/5308Immunoassay; Biospecific binding assay; Materials therefor for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896Neurological disorders, e.g. Alzheimer's disease
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/16Aptamers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/34Spatial arrangement of the modifications
    • C12N2310/344Position-specific modifications, e.g. on every purine, at the 3'-end
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00Applications; Uses
    • C12N2320/30Special therapeutic applications
    • C12N2320/34Allele or polymorphism specific uses
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/28Neurological disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne un aptamère caractérisé en ce qu’il possède la capacité de distinguer les conformères de fibres d’α-Syn de type F de la protéine α-Syn (α-Syn) des conformères de fibres d’α-Syn de type R, et en ce qu’il comprend une séquence spécifique d’acide ribonucléique (ARN) modifié ayant au moins 85% d’identité avec une séquence choisie parmi SEQ ID NO :1, SEQ ID NO :2, SEQ ID NO :3, SEQ ID NO :4, SEQ ID NO :5, SEQ ID NO :6, et SEQ ID NO :7, de préférence choisie parmi SEQ ID NO :1 et SEQ ID NO :2. La présente invention concerne en outre une composition ou un kit comprenant au moins de ces aptamères, ainsi que leurs utilisations in vitro. La présente invention porte également sur une méthode de diagnostic de synucléinopathies ainsi qu’une méthode de stratification, de suivi, de pronostic et d’évaluation de l’efficacité d’un traitement d’une synucléinopathie, comprenant l’utilisation d’au moins un aptamère et/ou une composition et/ou un kit susmentionné.
FR2105529A 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine Active FR3123357B1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
FR2105529A FR3123357B1 (fr) 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine
US18/564,121 US20240240191A1 (en) 2021-05-27 2022-05-25 Rna aptamers specific for a-synuclein protein fiber conformers
PCT/FR2022/050993 WO2022248805A1 (fr) 2021-05-27 2022-05-25 Aptameres arn specifiques de conformeres de fibres de la proteine a-synucleine
EP22732601.4A EP4347838A1 (fr) 2021-05-27 2022-05-25 Aptameres arn specifiques de conformeres de fibres de la proteine a-synucleine
JP2023572981A JP2024520044A (ja) 2021-05-27 2022-05-25 α-シヌクレインタンパク質繊維コンフォマーに特異的なRNAアプタマー

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2105529A FR3123357B1 (fr) 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine
FR2105529 2021-05-27

Publications (2)

Publication Number Publication Date
FR3123357A1 FR3123357A1 (fr) 2022-12-02
FR3123357B1 true FR3123357B1 (fr) 2024-04-12

Family

ID=76807799

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2105529A Active FR3123357B1 (fr) 2021-05-27 2021-05-27 Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine

Country Status (5)

Country Link
US (1) US20240240191A1 (fr)
EP (1) EP4347838A1 (fr)
JP (1) JP2024520044A (fr)
FR (1) FR3123357B1 (fr)
WO (1) WO2022248805A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024172061A1 (fr) * 2023-02-17 2024-08-22 国立大学法人京都大学 Aptamère d'arn

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2657953A1 (fr) 2005-07-19 2007-01-25 University Of Rochester Anticorps d'alpha-synucleine et techniques associees
CA3079909A1 (fr) 2017-10-23 2019-05-02 Carleton University Aptameres en tant qu'outil therapeutique pour prevenir l'agregation de proteines dans une maladie neurodegenerative

Also Published As

Publication number Publication date
EP4347838A1 (fr) 2024-04-10
FR3123357A1 (fr) 2022-12-02
US20240240191A1 (en) 2024-07-18
JP2024520044A (ja) 2024-05-21
WO2022248805A1 (fr) 2022-12-01

Similar Documents

Publication Publication Date Title
Lue et al. TREM 2 Protein Expression Changes Correlate with A lzheimer's Disease Neurodegenerative Pathologies in Post‐Mortem Temporal Cortices
Vergeer et al. Do labour market reforms reduce labour productivity growth? A panel data analysis of 20 OECD countries (1960–2004)
Simpson et al. Population variation in oxidative stress and astrocyte DNA damage in relation to Alzheimer‐type pathology in the ageing brain
FR3123357B1 (fr) Aptamères ARN spécifiques de conformères de fibres de la protéine α-synucléine
NZ625423A (en) Methods and compositions for diagnosis and prognosis of renal injury and renal failure
KR20220015394A (ko) 프라탁신 대체 요법의 유효성 결정을 위한 프라탁신 민감성 마커
BR112022003663A2 (pt) Método para tratar oftalmopatia tireoidiana (ted) em um indivíduo com ted; método para reduzir proptose em pelo menos 2 mm em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de diplopia em um indivíduo com oftalmopatia tireoidiana (ted); método para tratar ou reduzir a gravidade de oftalmopatia tireoidiana (ted); método para reduzir proptose em um olho em um indivíduo com oftalmopatia tireoidiana (ted); método para reduzir pontuação de atividade clínica (cas) de oftalmopatia tireoidiana (ted); método para a) reduzir proptose em pelo menos 2 mm e b) reduzir a pontuação de atividade clínica (cas) em um indivíduo com oftalmopatia tireoidiana (ted); e método para melhorar a qualidade de vida em um indivíduo com oftalmopatia tireoidiana (ted)
MX2020013229A (es) Endonucleasas cpf1 mutantes.
Yuan et al. Interferon-stimulated gene 15 expression in systemic lupus erythematosus.
Rocha-Resende et al. Immunomodulatory role of nonneuronal cholinergic signaling in myocardial injury
Tribouillard-Tanvier et al. Role of cyclophilin A from brains of prion-infected mice in stimulation of cytokine release by microglia and astroglia in vitro
MA38638A1 (fr) Marqueurs pour troubles liés à la sphingomyélinase acide et leurs utilisations
WO2011103330A3 (fr) Nouvelle phosphorylation de la troponine cardiaque i utilisée comme un moniteur de lésion cardiaque
EA202092612A1 (ru) Способ ферментативного дегуммирования масла
Wood et al. FKRP-dependent glycosylation of fibronectin regulates muscle pathology in muscular dystrophy
Wang et al. Long non‐coding RNA XIST alleviates sepsis‐induced acute kidney injury through inhibiting inflammation and cell apoptosis via regulating miR‐155‐5p/WWC1 axis
Meeus et al. Unravelling intracellular immune dysfunctions in chronic fatigue syndrome: interactions between protein kinase R activity, RNase L cleavage and elastase activity, and their clinical relevance
Klein et al. Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis
Casal et al. Serum markers of monocyte/macrophage activation in patients with Alzheimer's disease and other types of dementia
Said et al. Protein-synthesizing function and functional state of the liver of dogs at experimental toxocariasis
O'Rourke et al. Predicting beta-interferon failure in relapsing-remitting multiple sclerosis
JP2019500053A (ja) 代謝性疾患におけるマイクロrna
Gajofatto et al. Clinical and biomarker assessment of demyelinating events suggesting multiple sclerosis
MXPA05009251A (es) Composiciones y metodos para diagnosticar y tratar asma u otras enfermedades alergicas o inflamatorias.
Bonsignore et al. Mortality in Alzheimer’s disease

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20221202

PLFP Fee payment

Year of fee payment: 3

PLFP Fee payment

Year of fee payment: 4